The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.
Laurence Greenhill; Scott Kollins; Howard Abikoff; James McCracken; Mark Riddle; James Swanson; James McGough; Sharon Wigal; Tim Wigal; Benedetto Vitiello; et al. (Profiled Authors: Mark Riddle; Benedetto Vitiello)
Division of Child and Adolescent Psychiatry, New York State Psychiatric Institute/Columbia University, New York, NY 10032, USA. firstname.lastname@example.org
Journal of the American Academy of Child and Adolescent Psychiatry 2006;45(11):1284-93.
OBJECTIVE: The Preschool ADHD Treatment Study (PATS) was a NIMH-funded, six-center, randomized, controlled trial to determine the efficacy and safety of immediate-release methylphenidate (MPH-IR), given t.i.d. to children ages 3 to 5.5 years with attention-deficit/hyperactivity disorder (ADHD). METHOD: The 8-phase, 70-week PATS protocol included two double-blind, controlled phases, a crossover-titration trial followed by a placebo-controlled parallel trial. The crossover-titration phase's primary efficacy measure was a combined score from the Swanson, Kotkin, Atkins, M-Flynn, and Pelham (SKAMP) plus the Conners, Loney, and Milich (CLAM) rating scales; the parallel phase's primary outcome measure was excellent response, based on composite scores on the Swanson, Nolan, and Pelham (SNAP) rating scale. RESULTS: Of 303 preschoolers enrolled, 165 were randomized into the titration trial. Compared with placebo, significant decreases in ADHD symptoms were found on MPH at 2.5 mg (p<.01), 5 mg (p<.001), and 7.5 mg (p<.001) t.i.d. doses, but not for 1.25 mg (p<.06). The mean optimal MPH total daily dose for the entire group was 14.2 +/- 8.1 mg/day (0.7+/-0.4 mg/kg/day). For the preschoolers (n=114) later randomized into the parallel phase, only 21% on best-dose MPH and 13% on placebo achieved MTA-defined categorical criterion for remission set for school-age children with ADHD. CONCLUSIONS: MPH-IR, delivered in 2.5-, 5-, and 7.5-mg doses t.i.d., produced significant reductions on ADHD symptom scales in preschoolers compared to placebo, although effect sizes (0.4-0.8) were smaller than those cited for school-age children on the same medication.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
F X Castellanos; J Elia; M J Kruesi; W L Marsh; C S Gulotta; W Z Potter; G F Ritchie; S D Hamburger; J L RapoportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1996;14(2):125-37.
David J Posey; Michael G Aman; James T McCracken; Lawrence Scahill; Elaine Tierney; L Eugene Arnold; Benedetto Vitiello; Shirley Z Chuang; Mark Davies; Yaser Ramadan; et al.Biological psychiatry 2007;61(4):538-44.
A Sandler; C Glesne; G GellerChild: care, health and development 2008;34(1):111-20.
Appears in this Publication
Author of this Publication